Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Medpace Holdings, Inc. Announces Senior Leadership Changes

July 26, 2021 at 16:15 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Appointment of Jesse Geiger as President and Kevin Brady as Chief Financial Officer

Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced the appointment of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021. August Troendle will continue to serve as Medpace’s chairman and chief executive officer.

Geiger joined Medpace in 2007 as corporate controller and became chief financial officer in 2011. In 2014, Geiger expanded his role to include chief operating officer of laboratory operations. Geiger will continue to report to August Troendle. The newly created position of president will allow Troendle to continue to focus on the overall long-term strategic direction and success of the company.

“Jesse has played a key role during significant periods of growth in the company’s history, and we are fortunate to have his expertise to drive further growth for the company,” said Troendle. “This step positions Medpace for continued success as we accelerate the global development of safe and effective medical therapeutics.”

Kevin Brady, the current executive director of finance and treasurer, has been appointed to succeed Geiger as chief financial officer and will continue to report to Geiger. Brady brings diverse knowledge and experience to the role. Since joining Medpace in 2018, he has served as executive director of finance and treasurer and had oversight of all finance activities, including accounting, financial planning and analysis, investor relations, tax, internal audit and treasury. Prior to joining Medpace, Brady served as the vice president of finance for Myriad Genetics, Inc. from 2015 to 2018. Prior to Myriad, he spent 10 years at Procter & Gamble in various finance and accounting leadership positions. Brady started his career in the audit practice at Ernst & Young LLP.

“I am pleased to announce Kevin’s promotion to chief financial officer,” said Geiger. “Kevin has demonstrated strong leadership within the finance organization. I am confident he will continue to be a key member of the senior leadership team.”

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 4,100 people across 40 countries as of June 30, 2021.